Latest Carboplatin Stories
The era of one-size-fits-all medicine will eventually be history; after all it is no news that drugs and treatments do not work the same for everyone.
CALGARY, June 1 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.
CALGARY, May 25 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that it has opened enrollment in its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers.
CALGARY, May 21 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.
INDIANAPOLIS, May 20 /PRNewswire-FirstCall/ -- Results of two Phase II trials evaluating ALIMTAÂ® (pemetrexed for injection) in combination with a platinum chemotherapy and radiation for patients with locally advanced non-small cell lung cancer (NSCLC) will be presented by Eli Lilly and Company at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., on June 6, 2010. The standard of care for many patients with unresectable stage IIIA/B NSCLC is a...
SEATTLE, April 28 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
TAMPA, Fla., April 23 /PRNewswire/ -- Moffitt Cancer Center announces steadily growing interest in the ERCC1 Analysis, the first test developed for selecting chemotherapy for Non Small Lung Cancer patients.
Doctors are using a revolutionary treatment to help patients tolerate medications that they have been allergic to.
Ovarian cancer -- a major killer in woman -- has a new enemy, according to Austrian researchers who are hopeful a new antibody they found might step up the fight against the deadly disease.
CALGARY, March 30 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Cancer Therapy & Research Center at the University of Texas Health Science Center (CTRC) has started patient enrolment in a U.S.
- A serpent whose bite was fabled to produce intense thirst.